Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + interferon alfa-2a versus placebo + interferon alfa-2a in first-line metastatic clear cell renal cell carcinoma
2004-000282-35Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in clear cell renal cell carcinoma (ccRCC) comparing Bevacizumab + interferon alfa-2a with Placebo + interferon alfa-2a (2 arms). Primary endpoint: Overall survival. Started Aug 2004; status: completed.
02
Drugs
bevacizumabinterferon alfa-2a
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2004-000282-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000282-35.